Neuropathix, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania focused on the research and development of pain management and neuroprotective therapeutics.[1]
 | |
| Company type | Public |
|---|---|
| Expert Market: NPTX | |
| Industry | Pharmaceutical Biotechnology |
| Founders | Dean Petkanas, Thoma Kikis |
| Headquarters | Doylestown, Pennsylvania |
| Total assets | Patents US 9611213, US 10004722 |
| Website | neuropathix.com |
In 2016, through the company's subsidiary Kannalife, Neuropathix discovered KLS-13019[2][3][4] along with other therapeutic agents that prevent neuropathic pain, mitochondrial dysfunction, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[5] Neuropathix family of monotherapeutic small molecules are focused on treating oxidative stress-related diseases, inflammation, chronic pain management and neurodegenerative disorders.
In late 2021, Neuropathix subsidiary Kannalife, was awarded a non-dilutive three-year $2.97 Million grant from the National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH).[6] The three-year study grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for enhanced pain management and provides funding specifically in the Development of KLS-13019 for Neuropathic Pain.[7]
Neuropathix is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County to treat Chemotherapy-induced peripheral neuropathy, Hepatic encephalopathy, Mild Traumatic Brain Injury and CTE.[8]
References
edit- ^ Rees, Victoria (November 26, 2020). "Cannabinoid series: a CBD-inspired molecule to increase bioavailability". European Pharmaceutical Review. Retrieved 2020-11-26.
- ^ Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, Qian T, Chen Y, Cai Z, Petkanas D, et al. (April 2016). "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Medicinal Chemistry Letters. 7 (4): 424–8. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656. PMID 27096053.
- ^ Brenneman DE, Petkanas D, Kinney WA (September 2018). "Pharmacological Comparisons Between Cannabidiol and KLS-13019". Journal of Molecular Neuroscience. 66 (1): 121–134. doi:10.1007/s12031-018-1154-7. PMC 6150782. PMID 30109468.
- ^ Brenneman DE, Kinney WA, Ward SJ (August 2019). "Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity". Journal of Molecular Neuroscience. 68 (4): 603–619. doi:10.1007/s12031-019-01321-z. PMC 6615992. PMID 31077084.
- ^ Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ (April 2021). "Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS-13019 in mouse models of pain and reinforcement". British Journal of Pharmacology. 178 (15): 3067–3078. doi:10.1111/bph.15486. PMID 33822373. S2CID 233035597.
- ^ "Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)". finance.yahoo.com. 28 September 2021. Retrieved 2021-09-28.
- ^ "Development of KLS-13019 for Neuropathic Pain". reporter.nih.gov. Retrieved 2021-09-28.
- ^ Baskin, Ben (July 12, 2016). "How cannabis is helping one company research treatment of CTE". Sports Illustrated. Retrieved 2016-07-12.